Digital biomarkers: 3PM approach revolutionizing chronic disease management — EPMA 2024 position
Ivica Smokovski(PHI University Psychiatric Clinic - Skopje), Olga Golubnitschaja(University of Bonn), Nanette Steinle(University of Maryland, Baltimore), Günter Niklewski(Kraftanlagen (Germany)), Paolo Parini(Karolinska Institutet), Kneginja Richter(Nuremberg Hospital), Russell J. Andrews(Ames Research Center), Andrew Behnke(Carilion Clinic), Colin Birkenbihl(Harvard University), Godfrey Grech(University of Malta), Howard Bauchner(Boston University), Sonu Bhaskar(New South Wales Department of Health)
Cited by 62
Related Papers
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.4k
Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper
|Frontiers in Immunology|2020|519
Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging
|Particle and Fibre Toxicology|2010|491
Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016
|The EPMA Journal|2016|398
The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis
|The Lancet Public Health|2022|373